🔗 Share this article

While the US undertakes sweeping adjustments to its vaccine recommendations, one figure appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by questioning coronavirus vaccines during the global health crisis and has concentrated on possible deaths after Covid vaccination in her brief time at the FDA.

Scheduled Shifts to Pediatric Immunization Program

Health officials were set to announce sweeping changes to the childhood vaccine schedule recently, bringing the US with the Danish vaccine program, according to reports – a substantial departure that would put the US at odds with many the global community with no evidence for benefit. The planned update has been pushed back until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to speak at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to head the office this calendar year.

A New Direction at the Regulatory Body

This interim role might represent a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it points to a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has repeatedly called for discontinuing some pediatric immunization guidelines in the US in order to be more like the Danish model, a society with nationalized medicine and a citizenry approximately the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – usually the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Background

The appointee has little discernible background in pharmaceutical research, regulation or leadership, which has been customary for past directors of the biologics center. She has served at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for overseeing the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a sizeable institution. She is not an expert in industry regulation.”

Former commissioners of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she has not acquired the sort of resume that previous people who headed the center have had.”

CDER has an enormous workload at the agency, she emphasized.

“Everybody just zeroes in on the innovative therapies, but the generic program authorizes a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and so forth, and each of these must be supervised,” Woodcock said. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a major management element to the role, which manages more than 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” Woodcock concluded.

Official Statement and Disputed Programs

In response to inquiries about Dr. Høeg's qualifications and whether this selection signifies increased cooperation among agency officials on vaccines, a representative responded that the “questions are based on flawed presumptions”.

“Her resume matches the responsibilities of her job,” the representative stated, noting the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg inherits the commissioner’s new fast-track approval initiative, a disputed rapid therapy clearance system that allegedly worried her former heads. “How are these therapies being chosen for this fast-track system? Who takes the choices?” Howard said. “There’s a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards less stringent regulations of most medications, with the exception of shots.”

Public Past Work on Vaccines

With vaccines, Høeg has a clearer, if troubling, history, Howard said. She released a study using non-validated volunteer-provided data to estimate the incidence of myocarditis after Covid immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccines are riskier than they are.

Among her “desired changes” for the new government featured revising rules for novel immunizations and halting “non-essential” immunizations, she stated after the election on a audio program. At the agency, Dr. Høeg has allegedly suggested barring teenage boys from getting COVID-19 vaccines.

“She’s an thorough dogmatist who commences with her beliefs and tailors the evidence to accommodate the evidence in a extremely disingenuous, fraudulent manner,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined fellow skeptics, {like|